In an adult male with symptomatic genital HSV‑2 infection on the penis, does his sexual partner need to be tested and treated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Partner Management in Symptomatic Genital HSV-2 Infection

The sexual partner does not require treatment unless they develop their own symptomatic lesions, but they should be offered type-specific HSV-2 serologic testing and comprehensive counseling about transmission risk. 1, 2

Partner Testing and Counseling

HSV-2-seronegative partners should undergo type-specific serologic testing before continuing sexual activity, as disclosure and testing in HSV-2-discordant couples reduces transmission risk. 1 This testing distinguishes between:

  • Seronegative partners (at risk for acquisition) who need intensive prevention counseling 1, 2
  • Seropositive partners (already infected) who may have unrecognized infection and benefit from education about recognizing their own symptoms 3

Approximately 50% of HSV-2 seropositive individuals initially deny symptoms but can identify lesions after proper education about what to look for. 3

Transmission Prevention Strategy for the Infected Partner

The symptomatic male patient should receive:

First-episode treatment: Valacyclovir 1 g orally twice daily for 7-10 days 2, 4

After initial treatment, daily suppressive therapy with valacyclovir 500 mg once daily, which reduces transmission to susceptible heterosexual partners by approximately 48-50%. 2, 5 This also reduces asymptomatic viral shedding from 10.8% of days to 2.9% of days. 5

Critical Counseling Points for Both Partners

Sexual transmission occurs primarily during asymptomatic periods when no lesions are visible—this is the most common mode of HSV-2 spread. 5 Key behavioral modifications include:

  • Abstain from all sexual contact when visible lesions or prodromal symptoms are present 1, 2, 4
  • Recognize that transmission can occur even without visible lesions due to asymptomatic viral shedding 5, 4
  • Consistent latex condom use reduces transmission by approximately 50% from both men to women and women to men 1, 5
  • Combining daily suppressive therapy with consistent condom use provides additive protection, though neither eliminates transmission risk entirely 5

Common Pitfalls to Avoid

Do not assume episodic treatment reduces transmission risk—only daily suppressive therapy has been shown to reduce transmission to partners. 5

Do not rely solely on avoiding sex during visible outbreaks, as the majority of transmission occurs during asymptomatic periods when patients believe they are not infectious. 5, 6

Do not forget to counsel about oral-genital transmission, as HSV can be transmitted from oral lesions to genital sites through fellatio, and most persons with oral HSV are unaware they have it. 5

When Partners DO Need Treatment

Partners require their own treatment only if they develop:

  • Symptomatic genital lesions confirmed by viral culture, HSV DNA PCR, or HSV antigen detection 1, 4
  • First-episode symptoms warranting valacyclovir 1 g orally twice daily for 7-10 days 2, 4

Special Considerations

For HIV-infected individuals, routine type-specific serologic testing for HSV-2 should be performed, as HSV-2 increases HIV acquisition risk 3-fold. 1, 5 HIV-infected patients require higher antiviral doses. 1, 4

Women of childbearing age must inform obstetric providers about HSV-2 status during any pregnancy due to neonatal infection risk. 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of HSV-2 Reactive IgG

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Herpes Simplex Virus Type 2 (HSV-2) in Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Reducing HSV-2 Transmission Without Condoms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.